CYP11B1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL171635	0.44	17/20
Benzylimidazole (SCHEMBL414)	1.00	16/20
SCHEMBL8506	0.69	16/20
Pyroquilon (SCHEMBL22234)	0.54	16/20
Levoketoconazole (SCHEMBL8407)	1.00	14/20
Ketoconazole (SCHEMBL8408)	1.00	14/20
Levoketoconazole (SCHEMBL41473)	1.00	14/20
SCHEMBL168295	0.61	14/20
SCHEMBL12205	1.00	13/20
SCHEMBL77025	1.00	13/20
SCHEMBL160611	0.69	13/20
SCHEMBL79024	0.67	13/20
SCHEMBL91856	0.60	13/20
SCHEMBL57346	0.55	13/20
SCHEMBL30985	0.54	13/20
SCHEMBL56634	0.54	13/20
SCHEMBL154263	0.50	13/20
SCHEMBL104710	0.48	13/20
SCHEMBL171734	1.00	12/20
SCHEMBL146559	0.59	12/20

Clinical trials — most relevant to CYP11B1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance	PHASE4	NOT_YET_RECRUITING
The Role of Mineralocorticoid Receptors in Vascular Function	PHASE2/PHASE3	COMPLETED
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)	PHASE3	COMPLETED
Androgen Reduction in Congenital Adrenal Hyperplasia	PHASE2	WITHDRAWN
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer	PHASE2	RECRUITING
AMG 386 and Abiraterone for Advanced Prostate Cancer	PHASE2	COMPLETED
Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial	PHASE2	NOT_YET_RECRUITING
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Enoxolone in Major Depression - Biomarker-outcome Relationship	PHASE1/PHASE2	RECRUITING
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer	PHASE2	COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab	PHASE1	COMPLETED
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome	nan	COMPLETED
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
Connecting Breath and Mind for CYP With Long COVID	nan	UNKNOWN
Mutation Analysis of 17α-Hydroxylase	nan	UNKNOWN
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes	nan	NOT_YET_RECRUITING
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension	nan	UNKNOWN
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas	nan	UNKNOWN
Ascorbic Acid Treatment in Congenital Glucocorticoids and Mineralocorticoids Deficiency Due to NNT Mutation	nan	UNKNOWN
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN
Linear Growth of Children With Congenital Adrenal Hyperplasia	nan	UNKNOWN
68Ga-Pentixafor PET/CT for Guiding Surgical Treatment of Primary Aldosteronism With Bilateral Adrenal Lesions	nan	COMPLETED
Cholesterol Metabolites as Markers for CYP3A Induction	nan	COMPLETED
Effects and Interactions of Liquorice and Grapefruit on Glucocorticoid Replacement Therapy in Addison's Disease	nan	COMPLETED
Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP11B1 binder may also engage these)

Protein	Name	Similarity
CYP11B2	Cytochrome P450 11B2, mitochondrial	1.000	landscape →
Q29527	—	1.000	Q29527 →
P51663	—	0.986	P51663 →
P15150	—	0.983	P15150 →
Q29552	—	0.977	Q29552 →
P30100	—	0.957	P30100 →
Q64658	—	0.951	Q64658 →
P30099	—	0.951	P30099 →
CYP4A11	Cytochrome P450 4A11	0.942	landscape →
P15539	—	0.942	P15539 →
P14580	—	0.934	P14580 →
Q07217	—	0.929	Q07217 →
CYP4A22	Cytochrome P450 4A22 (CYPIVA22) (Fatty acid o	0.923	landscape →
P10611	—	0.922	P10611 →
CYP46A1	Cholesterol 24-hydroxylase	0.921	landscape →
Q9WVK8	—	0.920	Q9WVK8 →
P14579	—	0.919	P14579 →
Q9GJX5	—	0.916	Q9GJX5 →
Q5SUV1	—	0.915	Q5SUV1 →
Q64408	—	0.915	Q64408 →
Q5RJL2	—	0.915	Q5RJL2 →
Q8N8L6	—	0.913	Q8N8L6 →
P14581	—	0.912	P14581 →
Q86XA0	—	0.911	Q86XA0 →
Q86WI3	—	0.911	Q86WI3 →
P97720	—	0.910	P97720 →
Q9QXJ4	—	0.909	Q9QXJ4 →
CYP2F1	Cytochrome P450 2F1 (EC 1.14.14.1) (CYPIIF1)	0.908	landscape →
Q8SPK0	—	0.908	Q8SPK0 →
A6NKP2	—	0.905	A6NKP2 →